$RLFTF Relief's website updated: "How long will i
Post# of 653
Assuming that the top-line are positive, the FDA could at that time consider granting EUA, which would permit the drug to be launched in Q1 2021.
A New Drug Application (NDA) submission requesting marketing approval would be filed based on positive top-line results. Full NDA approval could be granted to RLF-100 for the US market by Q3 2021.
The FDA granted RLF-100™ fast track designation, which, among other things, makes RLF-100™ eligible for Priority Review if relevant criteria are met.
Priority Review designation means the FDA’s goal is to take action on an application within 6 months compared to 10 months under standard review.
It would be reasonable to expect Priority Review for applications filed under the Coronavirus Treatment Acceleration Program (CTAP). RLF-100TM is part of this program, which was promulgated by the FDA earlier this year in express response to the emergence of the COVID-19 pandemic."
- Alexandre